Breaking News

Amgen Appoints CFO

June 10, 2014

Meline to head finance and investor relations operations

David W. Meline has been appointed executive vice president and chief financial officer of Amgen, effective July 21. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and chief executive officer. Mr. Meline succeeds Michael A. Kelly, who served as acting CFO since January 2014.
Mr. Meline joins the company from 3M, where he most recently served as senior vice president and chief financial officer, responsible for all financial activities for 3M across 70 countries. Previously, he held several leadership roles at General Motors, working on five continents during his tenure.
Mr. Bradway said, "David's leadership talent and broad international experience will be invaluable to Amgen as we execute our strategy for long term growth and bring our pipeline of medicines toward commercialization in a number of new markets. I am delighted to welcome him to the team."
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision